Researcher Develop Drinkable, Carbon Monoxide-Infused Foam To Enhance Effectiveness of Cancer Therapy

Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment? That was the intriguing question that led University of Iowa researchers and their colleagues to develop a drinkable, carbon monoxide-infused foam that boosted the effectiveness of the therapy, known as autophagy inhibition, in mice and human cells. The findings were recently published in the journal Advanced Science. 

Looking for ways to exploit biological differences between cancer cells and healthy cells is a standard approach for devising new cancer treatments. But it is a painstaking process that requires a deep understanding of complex cancer biology and often a dose of unexpected insight. 

The potential of autophagy inhibitors 

Researchers have known for several decades that autophagy, which is the cell’s natural recycling system, is increased in cancer cells relative to healthy cells, suggesting that inhibiting autophagy might be a way to target cancer cells. However, results from almost 20 clinical trials testing autophagy inhibitors have been inconclusive.

"Within those clinical trials they found mixed results; there was some benefit, but for many patients there was no benefit, which really pushed researchers back to the drawing board,” says James Byrne, MD, PhD, UI assistant professor of radiation oncology and biomedical engineering and senior author on the new study. 

Searching for insight into why autophagy inhibition only seems to work some of the time, the researchers made the surprising discovery that smokers in two of the previous trials of autophagy inhibitors seemed to do better than non-smokers.

Carbon monoxide boosts anti-cancer activity of autophagy inhibition 

The team already had just such a “platform” to test their ideas. Byrne specializes in crafting gas-entrapping materials (GEMs)—foams, gels, and solids made from safe, edible substances that can be infused with different gas molecules. For this study, the researchers created a drinkable foam infused with carbon monoxide. 

When mice with pancreatic and prostate cancers were fed the carbon monoxide foam and simultaneously treated with an autophagy inhibitor, tumor growth and progression was significantly reduced in the animals. The team also showed that combining carbon monoxide with autophagy inhibitors had a significant anti-cancer effect in human prostate, lung, and pancreatic cancer cells in petri dishes.

Ultimately, Byrne hopes to test this approach in human clinical trials.

“The results from this study support the idea that safe, therapeutic levels of CO, which we can deliver using GEMs, can increase the anti-cancer activity of autophagy inhibitors, opening a promising new approach that might improve therapies for many different cancers,” he says. 

Reference: Bi J, Witt E, McGovern MK, et al. Oral carbon monoxide enhances autophagy modulation in prostate, pancreatic, and lung cancers. Adv Sci. 2023:2308346. doi: 10.1002/advs.202308346

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.